Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer

March 14th 2022, 2:13pm

PER® New York GU

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Biomarkers Allow for Tailoring TNBC Treatments

March 5th 2022, 10:11pm

PER® Miami Breast Cancer Conference

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Abemaciclib/Endocrine Therapy Combo Showcases Long-Term Clinical Benefit in HR+ High-Risk Early Breast Cancer

March 5th 2022, 5:20pm

PER® Miami Breast Cancer Conference

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Addressing Cardiotoxicity in Breast Cancer Requires Multifaceted Approach

March 5th 2022, 1:39pm

PER® Miami Breast Cancer Conference

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer

March 5th 2022, 11:00am

PER® Miami Breast Cancer Conference

Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.

Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development

March 4th 2022, 10:24pm

PER® Miami Breast Cancer Conference

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

Neoadjuvant Immunotherapy/Chemotherapy Combos Gain in Prominence for Early-Stage TNBC

March 4th 2022, 7:40pm

PER® Miami Breast Cancer Conference

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Breast Cancer Research Begins With Curiosity

March 4th 2022, 6:50pm

PER® Miami Breast Cancer Conference

Getting a start in clinical research can appear daunting, said Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C). Fortunately, all it really takes is a question and a bit of drive.

ctDNA Assays Open the Door for Earlier Detection, Intervention in Breast Cancer

March 4th 2022, 5:00pm

PER® Miami Breast Cancer Conference

Pat W. Whitworth, MD, explains how data from past studies are informing the use of circulating tumor DNA and talks about the potential of these assays to guide treatment decisions in patients with breast cancer.

Loprinzi Shares Top Concerns, Best Practices for Treatment-Related Toxicity Management in Breast Cancer

March 4th 2022, 4:00pm

PER® Miami Breast Cancer Conference

Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.

Chemoimmunotherapy Anchors Frontline Treatment in Metastatic TNBC

March 4th 2022, 3:28pm

PER® Miami Breast Cancer Conference

Patients with newly diagnosed metastatic triple-negative breast cancer should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy.

Real-World Data Describe Eribulin Efficacy After Novel Agents for MBC

March 4th 2022, 2:30pm

PER® Miami Breast Cancer Conference

Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.

Miami Breast Cancer Conference Agenda Takes a Multidisciplinary Approach to Care

March 3rd 2022, 3:44pm

PER® Miami Breast Cancer Conference

The 39th Annual Miami Breast Cancer Conference® makes its return to the Fontainebleau Miami Beach in Florida with a twist on both the agenda and the setting.

Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML

February 28th 2022, 9:40pm

PER® Congress on Hematologic Malignancies (Winter Hem)

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

Checkpoint Inhibitors and Bispecifics Build Momentum Throughout Lymphoma

February 28th 2022, 9:11pm

PER® Congress on Hematologic Malignancies (Winter Hem)

Although checkpoint inhibitors and bispecific antibodies have come to represent clinical oncology’s fourth leg of treatment—immunotherapy—there remains much to explore within lymphoma.

Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCL

February 28th 2022, 3:00pm

PER® Congress on Hematologic Malignancies (Winter Hem)

The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence

February 20th 2022, 5:40pm

Genitourinary Cancers Symposium (ASCO GU)

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

Adjuvant Pembrolizumab Maintains DFS Benefit in High-Risk RCC

February 20th 2022, 3:44pm

Genitourinary Cancers Symposium (ASCO GU)

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

Superior Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC

February 19th 2022, 9:12pm

Genitourinary Cancers Symposium (ASCO GU)

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

Lenvatinib Plus Pembrolizumab Produces Consistent Efficacy in East Asian Subset With Advanced RCC

February 19th 2022, 8:38pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.